Palo Alto Networks Inc (NYSE:PANW, ETR:5AP) shares fell afterhours despite the cybersecurity firm reporting better-than-expected financial results for the fiscal third quarter.
The company reported a 15% year-over-year jump in revenue to $2.3 billion for the April quarter, slightly above estimates of $2.28 billion.
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later in 2025, according to Jefferies analysts, following another batch of positive clinical trial results from Beckley Psytech’s BPL-003 program targeting treatment-resistant depression (TRD).
Beckley Psytech’s Phase 2a study of BPL-003, an intranasal form of 5-MeO-DMT, showed that a single dose of the therapy along with selective serotonin reuptake inhibitor (SSRI) therapies, produced rapid, robust, and sustained antidepressant effects.
Victoria's Secret & Co. (NYSE:VSCO) has adopted a limited-duration shareholder rights plan, commonly referred to as a “poison pill,” to prevent a potential hostile takeover attempt by Australian billionaire Brett Blundy’s investment firm BBRC.
BBRC has steadily increased its stake in Victoria’s Secret to about 13% of its outstanding shares, including acquiring shares in violation of US antitrust laws by failing to file the required forms for three years. The company has now corrected this, which could allow it to acquire up to 49.99% of Victoria’s Secret’s voting shares as soon as May 21, Victoria's Secret said on Tuesday.
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares jumped more than 6.5% on Tuesday after the US Food and Drug Administration unveiled a new framework for COVID-19 vaccine approvals that analysts said largely maintains the status quo for the company’s core market.
The FDA’s updated guidance does not change how COVID-19 vaccines are authorized for individuals aged 65 and older or those aged six months to 64 years who are at high risk. These groups, which analysts estimate account for a majority of COVID-19 vaccinations, will continue to receive annual shots without the need for new placebo-controlled trials.
Tesla Inc (NASDAQ:TSLA) CEO Elon Musk has committed to leading the electric vehicle maker for the next five years while scaling back his political spending during an interview at Bloomberg’s Qatar Economic Forum 2025 in Doha.
Musk said that his decision is driven by the desire to maintain "sufficient voting control" over the company's future rather than financial incentives.
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline data from Part 2 of Beckley Psytech’s Phase 2a study of BPL-003, an intranasal formulation of mebufotenin benzoate, in combination with selective serotonin reuptake inhibitors (SSRIs) for treatment-resistant depression (TRD).
The open-label Phase 2a study evaluated the safety, efficacy, and pharmacokinetics of a single dose of BPL-003 in 12 patients with moderate-to-severe depression who had not responded to at least two prior treatments and were taking SSRIs.
Shares in neuroscience analytics firm IXICO PLC (LSE:IXI, OTC:PHYOF) rose 11% on Tuesday after the company said it was well placed to meet or exceed full-year expectations, citing stronger trading, new contract wins and disciplined execution of its strategy.
In a note published the same day, Cavendish Securities reiterated its 'buy' rating and set a 24p price target, more than double IXICO’s current share price of 10p.